OncoMatch/Clinical Trials/NCT06315309
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Is NCT06315309 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ATG Combined with Tacrolimus and Mini Methotrexate for gvhd,acute.
Treatment: ATG Combined with Tacrolimus and Mini Methotrexate — The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin \[ATG\]) will help prevent the development and/or improve severity of acute and/or chronic GVHD.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Prior therapy
Cannot have received: autologous hematopoietic stem cell transplant
Exception: allowed if > 3 months prior to enrollment
Autologous hematopoietic stem cell transplant < 3 months prior to enrollment
Cannot have received: allogeneic stem cell transplant
Previous allogeneic stem cell transplant
Lab requirements
Kidney function
creatinine clearance > 50 mL/min (Cockcroft-Gault formula, actual body weight)
Liver function
total bilirubin < 1.5x ULN (Gilbert's Disease allowed up to <3mg/dl); ALT/AST < 2.5x ULN
Cardiac function
Ejection fraction ≥ 45%
Cardiac function: Ejection fraction ≥ 45%; Calculated creatinine clearance greater than 50 mL/minute (using the Cockcroft-Gault formula and actual body weight); Liver function: total bilirubin < 1.5x the upper limit of normal and ALT/AST < 2.5x the upper normal limit. Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin value up to <3mg/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify